1260610-90-9

Basic information

• Product Name: (R)-4-benzylmorpholine-2-carboxylic acid
• Synonyms: (R)-4-benzylmorpholine-2-carboxylic acid;2-Morpholinecarboxylic acid, 4-(phenylmethyl)-, (2R)-
• CAS NO: 1260610-90-9
• Molecular Formula: C12H15NO3
• Molecular Weight: 221.25
• Mol File: 1260610-90-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 372.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.235±0.06 g/cm3(Predicted)
• PKA: 2.57±0.20(Predicted)
• CAS DataBase Reference: (R)-4-benzylmorpholine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-benzylmorpholine-2-carboxylic acid(1260610-90-9)
• EPA Substance Registry System: (R)-4-benzylmorpholine-2-carboxylic acid(1260610-90-9)

Safety Data

• Hazardous Substances Data: 1260610-90-9(Hazardous Substances Data)

Usage

General Description

(S)-4-benzyl-morpholine-2-carboxylic acid is a chemical compound with the molecular formula C14H17NO3. It is a derivative of morpholine and belongs to the class of carboxylic acids. (S)-4-benzyl-morpholine-2-carboxylic acid is a chiral molecule with an asymmetric carbon center, and the (S)-enantiomer refers to its stereochemistry. It is commonly used in the synthesis of pharmaceuticals, particularly in the development of new drugs for various therapeutic applications. The presence of the benzyl and morpholine groups in the molecule confers specific properties and biological activities to this compound, making it a valuable building block for drug discovery and development. Additionally, its carboxylic acid functionality allows for the formation of esters, amides, and other derivatives, further expanding its potential applications in chemical and pharmaceutical research.

Upstream product

• 7732-18-5 water 
• 135782-29-5 methyl 4-benzylmorpholine-2-carboxylate 
• 135072-15-0 4-benzylmorpholine-2-carboxylic acid hydrochloride 
• 147767-51-9 4-benzyl-2-cyanomorpholine 
• 104-63-2 N-Benzylethanolamine 
• 1030837-47-8 n-butyl 4-benzylmorpholine-2-carboxylate 

Downstream Products

• 868689-63-8 (S)-2,4-morpholinedicarboxylic acid 4-(1,1-dimethylethyl)ester 
• 1305117-43-4 1-(4-benzylmorpholin-2-yl)ethanamine 
• 1332352-39-2 (S)-(4-benzylmorpholin-2-yl)(morpholino)methanone methanesulfonate 
• 1120335-11-6 (S)-(4-benzylmorpholin-2-yl)(morpholino)methanone 
• 852237-32-2 4-benzyl-N-methoxy-N-methylmorpholine-2-carboxamide 
• 1227912-13-1 N-{2-[4-(methyloxy)phenyl]-2-oxoethyl}-4-(phenylmethyl)-2-morpholinecarboxamide 
• 1227911-88-7 N-[2-(4-chlorophenyl)-2-oxoethyl]-4-(phenylmethyl)-2-morpholinecarboxamide 
• 1227911-94-5 N-[(1R,2R)-2-hydroxycyclohexyl]-4-(phenylmethyl)-2-morpholinecarboxamide 
• 1227912-07-3 N-[2-(3-chlorophenyl)-2-oxoethyl]-4-(phenylmethyl)-2-morpholinecarboxamide 
• 1227912-01-7 N-(2-oxo-2-phenylethyl)-4-(phenylmethyl)-2-morpholinecarboxamide 

Relevant articles and documents

Practical asymmetric synthesis of an edivoxetine·HCl intermediate via an efficient diazotization process

A convergent synthesis of (S)-(4-benzylmorpholin-2-yl)(morpholino)methanone methanesulfonate (1), a key regulatory starting material for edivoxetine·HCl, was developed at Eli Lilly & Company. This novel synthesis utilizes d-serine as the source of chirali

A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. The invention provides a compound, which has excellent activity and solubility and is more efficiently formulated and delivered, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 comprising the same.

Enantioselective synthesis of (R)- and (S)-N-Boc-morpholine-2-carboxylic acids by enzyme-catalyzed kinetic resolution: application to the synthesis of reboxetine analogs

The (R)- and (S)-N-Boc-morpholine-2-carboxylic acids 9 and 10 were prepared using an enantioselective synthesis employing a highly selective enzyme-catalyzed kinetic resolution of racemic n-butyl 4-benzylmorpholine-2-carboxylate (11) as the key step. Acids 9 and 10 were then converted efficiently and stereoselectively to reboxetine analogs 3 and 4.